All Online

1 - 12 of 46 results

Refine

Active filters

Diabetes Mellitus, Type 2
1 CME CREDIT

This educational initiative was developed to educate primary care providers on the benefits of early insulin therapy, when to initiate insulin therapy in patients with type 2 diabetes, the advantages and disadvantages of various insulin regimens, and the current data for new and emerging basal insulin formulations.


ACHL Diabetes Patient Case Study

Diabetes continues to have a significant impact on morbidity and mortality in the United States, and is an ongoing treatment challenge for primary care providers who lack confidence with treatment intensification including newer agents and combination therapies resulting in clinical inertia. Further, approaches to improved adherence and lifestyle modification through shared-decision making continue to evolve with the goal of improving quality of care.


sugar stacked with the word diabetes

The expanded number of therapies with varying mechanisms of action for type 2 diabetes has resulted in novel combination regimens for patients not achieving goals despite therapy with metformin. Dr. Serge Jabbour will review novel combinations and approaches to intensifying therapy in this interactive case study.


In this interactive case study, Dr. Richard Pratley, Medical Director of the Florida Diabetes Institute, walks through the clinical decision-making process for a 60-year-old African American woman with type 2 diabetes whose diabetes is progressing despite metformin therapy. Dr. Pratley examines factors likely contributing to this patient's poor glycemic control, as well as steps for intensification of therapy beyond metformin and considerations for treatment selection, such as risk for hypoglycemia and cardiovascular issues.


In this case presentation, Kathleen Wyne, MD, PhD, Associate Professor of Clinical Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism at The Ohio State University College of Medicine shares strategies for intensification of diabetes management that incorporate real life patient challenges with evidence based medicine to develop a regimen that is likely to attain the patient’s A1C target. These strategies include working with what the patient is actually willing to do while trying to attain A1C target, with consideration to importance of controlling both fasting and postprandial glucose in patients with type 2 diabetes, and the use of GLP-1 receptor agonists in combination with basal insulin for optimal glycemic control in patients who require intensification of therapy.


middle aged woman with a headache

This program is designed to increase the knowledge and confidence of primary care healthcare professionals (HCPs) with the goal of individualizing therapy with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of adult patients with type 2 diabetes mellitus (T2DM). In this interactive case study of a simulated patient, participants will be able to identify and address individual challenges that they may normally encounter in their clinical practices.


This program is designed to increase the knowledge and confidence of primary care healthcare professionals (HCPs) with the goal of individualizing therapy with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of adult patients with type 2 diabetes mellitus (T2DM). In this interactive case study of a simulated patient, participants will be able to identify and address individual challenges that they may normally encounter in their clinical practices.


three patients with different ethnicities have diabetes

With an ever-increasing array of oral and injectable treatment options available for management of patients with type 2 diabetes mellitus (T2DM) at all stages of the disease, it is more challenging than ever for clinicians to appropriately select and titrate antihyperglycemic agents. In this case compendium, Vivian Fonseca, MD, Professor of Medicine and Pharmacology and Chief, Section of Endocrinology at Tulane University Health Sciences Center, New Orleans, presents three patient cases at different stages of T2DM in order to illustrate how clinicians can set treatment goals, select therapies, monitor response, and intensify therapy in both the newly diagnosed patient and one with long-standing disease and multiple comorbidities.


4 empty vials
1.5 CME CREDITS

In recent years, new and emerging therapies including new insulin formulations and delivery, as well as new agents to use in combination have been developed allowing for a greater individualization of T2DM therapy. These have included concentrated and basal insulins and the growing presence of incretin-based therapies. These new therapeutics are helpful in preventing post-prandial hyperglycemia often seen in T2DM. This activity will provide up-to-date education on the application and efficacy of these new and emerging options to individualizing treatment and improve patient outcomes by reducing glycemic variability.